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Abstract. This paper reports the effects of a placebo-controlled Se-enriched yeast supplementa-
tion trial, conducted for 14 months, on arsenism in adult farmers living in a rural community in
Inner Mongolia, China. The farmers had been naturally exposed to elevated concentrations of As in
drinking water from tube-wells since 1983 but changed to ‘arsenic-free’ drinking water when the
trial began in June 1996. Blood and hair Se and As concentrations were analysed pre-intervention
and at the end of the 3rd, 9th and 14th month, while skin lesions were assessed pre-intervention,
as well as at the end of the 14th month, using the Arsenism Clinical Criteria established by the
Ministry of Health, China. As the trial was a voluntary one, a number of farmers did not routinely
have their blood and hair samples taken for analysis. Consequently, the data have been analysed
in two categories. Fifty-four farmers from the Se-group and 29 from the placebo-group who were
sampled on each occasion were considered as one group, which has been compared with the second
group comprising up to a total of 100 farmers in the Se-group and 86 in the placebo-group. Results
calculated for those farmers who were sampled on each occasion, showed that at the end of the trial,
blood and hair Se concentrations of the Se-group increased from 0.130 to 0.186µg ml−1 and from
0.431 to 0.502µg g−1, respectively, while those of the placebo-groups remained constant. Blood
and hair As concentrations of the Se-group decreased from 0.051 to 0.015µg ml−1 and from 2.57
to 0.680µg g−1, respectively, a greater reduction than those in the placebo-group that went from
0.064 to 0.024µg ml−1 and from 2.62 to 1.25µg g−1, respectively. When the data from all patients
were examined, the analytical trends were similar. An evaluation of skin lesions in the category who
were sampled for hair and blood on each occasion showed that 41.2% of hyperkeratosis, 50.0% of
depigmentation and 44.7% of pigmentation in the Se-group improved one or more degrees, while
those in the placebo-group improved by only 7.1, 12.0 and 6.7%, respectively. A total of 61.1% of
the adults in Se-group improved in one or more type of skin lesion, but only 17.2% improved in the
placebo-group. Comparable results were obtained when all the data from both categories of farmers
were examined. Results from the trial showed that Se supplementation was more effective for the
improvement of adults who were affected by double or triple skin lesions. In the placebo-group, most
of the severely affected adults improved in only one kind of skin lesion, but in the Se-group, more
adults improved in two or three kinds of skin lesions. Although the trial was limited by its relatively
small size, the results have provided some evidence of the usefulness of Se supplementation for
people affected by arsenism.
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1. Introduction
Inorganic arsenic is widely recognised as a human carcinogen (WHO IARC, 1980).
Epidemiological studies have shown that long-term exposure to As can cause
serious health effects (Saha et al., 1999) including, skin cancer (Tseng et al., 1968;
Guo et al., 1998), lung and bladder cancer (Chiou et al., 1995; Moore et al., 1997),
or other internal cancers (Bates et al., 1992). It can also cause other non-cancer
end-point diseases, including diabetes (Rahman et al.,1998), disturbances of the
vascular system including peripheral vascular disease (Tseng et al., 1997), cerebro-
vascular disease (Chiou et al., 1997), ischemic heart disease (Hsueh et al., 1998)
and hypertension (Rahman et al., 1999). The commonest hallmark of chronic As
exposure is the development of skin lesions, such as hyperkeratosis, depigment-
ation and pigmentation. Patients with As-related skin lesions are at risk of de-
veloping severe health effects (Brown, 1998). Most adults in elevated drinking
water As exposure areas in China-Taiwan are affected by serious skin lesions
(Tseng et al., 1968). Although chelating agents, such as D-penicillamine, 2,3-
dimercaptosuccinic acid (DMSA) and 2,3-dimercapto-1-propane sulfonate
(DMPS), have been tried in chronic arsenism (synonymous with arseniasis and
arsenicism) therapy (Aposhian et al., 1997, 2000; Mazumder et al., 1998), no
clinical benefits have been found except for reducing the As stored in the body.
Some studies have shown that adults once affected by skin lesions may not recover
even after remediation of the arsenic exposure (Tseng et al., 1968).
Selenium has been widely recognised as a nutritional element protecting hu-
mans from cancers (Whanger, 1992; Alaejos et al., 2000), cirrhosis, diabetes, and
cardiovascular pathologies (Navarro-Alarcon and Lopez-Martinez, 2000). It has
also been known for many years to be an antagonist of As toxicity (Levander,
1977). Experiments show that Se can increase As biliary excretion (Levander,
1977) and urinary excretion in experimental animals (Biswas et al., 1999). It ap-
pears to antagonise several cellular effects of arsenic in biological systems
(Kosnett, 1999) and can protect against arsenic-induced chromosomal damage in
cultured human lymphocytes (Sweins, 1983).
As many endemic arsenism areas in the world are rural or under-developed
areas deficient in some nutrients (Chen et al., 1988), a low Se intake may influence
the development of arsenism (Valentine et al., 1994). Epidemiological studies in
China-Taiwan have shown that there are close negative correlations between Se
and As in ‘blackfoot disease’ (arsenism) patients’ hair (Wang et al., 1994), urine
(Wang, 1996), blood (Wang et al., 1993) and bone (Wang et al., 1997).
Selenium supplementation has been widely used to control Keshan and Kaschin-
Beck diseases in China (Tan et al., 1987; Yang, 1987). It has also been used to
prevent some types of cancers (Blot, 1997; Combs and Gray, 1998). Trials results
showed that Se supplementation can significantly reduce the lung cancer incidence
in tin miners (Xuan et al., 1991), where airborne arsenic exposure may be one of
the factors (Qiao et al., 1997).
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Selenium, an antioxidant nutrient that antagonises many of the effects of As
in biological systems, merits attention as a potential therapeutic agent for patients
with a history of chronic As exposure (Kosnett, 1999). The primary objective of
this research was, therefore, to test the effectiveness of Se supplementation during
a 14-month trial (June 1996 to August 1997) of arsenism in adult farmers in Inner
Mongolia. As both the exposed farmers and the local government have realised the
urgency of the cessation of elevated As exposure, the trial commenced at the same
time as the local authority installed a new drinking water supply system containing
As concentrations of <50µg L−1 (referred to as ‘As-free’ drinking water). This pa-
per then, reports on a placebo-controlled intervention trial involving both a change
to ‘As-free’ drinking water and Se supplementation of adult farmers. As arsenism is
a serious disease no controls were established, for ethical reasons, involving local
farmers continually exposed to As in drinking water.
We mainly discuss the effects of Se supplementation on As and Se concentra-
tions in hair and blood and on the skin lesions. In earlier papers we have reported
on the clinical stages of arsenism and their relationship with hair As concentrations
(Yang et al., 2000, 2002b) and concentration of As in drinking water and skin
lesions (Yang et al., 2002a) at rural sites in Inner Mongolia.
2. Materials and methods
2.1. STUDY AREA
The study was conducted by staff from the Institute of Geographical Sciences
and Natural Resources Research, Chinese Academy of Sciences, Beijing, in co-
operation with doctors from the Institute of Endemic Disease Control and Research,
Hohhot, Inner Mongolia, and the local authorities. The study area is located in a
rural district in Azuo County, Inner Mongolia containing 2085 people, comprising
450 households living in 19 villages. The residents are Chinese or Mongolian. All
are local rural farmers living under poor economic conditions and their daily food
is mainly local crops, with very limited As concentrations.
In 1983, the villagers’ drinking water resources were changed from limited
surface water supplies to groundwater wells with hand-pumps. However, more than
75% of the drinking water wells were contaminated with As, compared with the
national drinking water standard of 50µg L−1 (MOH, 1985) and more than 90% of
the population was exposed to As. Some 311 adults were identified with arsenism
living in the district at a prevalence rate of 15% (Sun et al., 1994). ‘Arsenic-free’
drinking water was supplied to the villagers from June 1996 when the trial was
initiated.
2.2. TRIAL SUBJECTS
Adults from 19 villages were divided into two groups by village. Adults from nine
villages were supplemented with Se-yeast tablets (the Se-group) while adults in 10
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other villages were treated with placebo tablets (the placebo-group). Grouping by
village was adopted to lessen possible tablet exchange between individuals within
any one village. One hundred adults formed the Se-group and 86 the placebo-
group and were checked for effects of Se supplementation on the development
of arsenism lesions during a 14-month trial.
As the trial involved adult volunteers in a rural district, not every person at-
tending the skin evaluation interviews had hair and blood samples collected for
chemical analysis during each sample period. Consequently, the results are presen-
ted for the 54 farmers (28 males and 26 females) in the Se-group and 29 farmers
(14 males and 15 females) in the placebo-group who were sampled for analysis on
every occasion. Approximately half of the farmers in each group lie within the
40–49 age group. These results are presented initially, and are compared sub-
sequently with data for all the farmers in the trial. All the adults were under the
supervision of the local doctors throughout the trial.
2.3. SELENIUM SUPPLEMENTATION METHOD
The tablets for the Se-group were made of Se-enriched yeast with a starch binder.
Each tablet contained 100µg organic Se (0.25 mg yeast). The placebo tablet, con-
taining <1µg Se per tablet, was made of starch binder and resembled the Se tablet.
Two tablets of Se-enriched yeast were provided each day for the Se-group during
first 3 months, then one tablet a day in the second 3 months, two tablets a day in the
third 3 months (by the 9th month) and one tablet per day for the last 5 months (by
the 14th month). The dose was varied as we were unsure whether a continuous dose
of 200µg Se/day may itself give rise to health effects. Neither the doctors from the
Institute of Endemic Disease Control and Research undertaking the evaluation of
skin lesions, nor the adults in the trial knew which type of tablet they received.
2.4. CLINICAL SURVEY
The clinical diagnosis interviews were conducted before the trial began, and at
the end of the 14th month following provision of the tablets. The diagnosis was
carried out by the doctors who examined for signs of hyperkeratosis, pigmenta-
tion and depigmentation following standard Chinese Endemic Arsenism Clinical
Diagnosis Guidelines as shown in Table I (MOH, 1994). Each person was ex-
amined by two doctors and evaluated separately. As both doctors were working
to the same Chinese arsenism clinical standards (MOH, 1994) results were similar.
When individual evaluations were different, the patient was re-examined and the
results discussed by the doctors to reach agreement. The adults were considered
as ‘improved’ if their skin lesions disappeared or were reduce by 1◦ after the trial
period.
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TABLE I
Clinical criteria for endemic arsenism skin lesions (MOH, 1994)
1◦ 2◦ 3◦
Hyperkeratosis Some hyperkeratosis
pimples on the
non-scrub parts of
palms of hands or
feet; the pimple’s
diameter like a
needlepoint
More hyperkeratosis
pimples on palms of
hands or feet and the
diameter like a grain
Speckled hyperkerato-
sis on hands or
feet; hyperkeratosis
pimples on the back
of hands or feet
Depigmentation White depigmentation
points on chest,
stomach or back, like
needle points
Depigmentation larger
points as grain and
extending to legs or
arms
Depigmentation points
even larger, more
densely distributed
over whole body and
joined together
Pigmentation Some little dark points
located on body, or
skin colour a shade
dark
Dark points, or skin col-
our darker brown
Darker points or skin
colour black
2.5. SAMPLING
Hair and blood was sampled before the experiment and at the end of the 3rd, 9th
and 14th month of the trial. About 5 g new growth hair was cut from around the
nape of the neck of each adult using stainless steels scissors. Blood samples were
collected by a specialist via arm vein puncture and the samples stored in plastic test
tubes at 4 ◦C, with a drop of heparin added as anticoagulant. All the samples were
taken back to the Laboratory of the Institute of Geographical Sciences and Natural
Resources Research in Beijing for analyses within 1 week of collection. Analyses
over time showed that more than 99% of the As remained in the blood samples.
2.6. ANALYSES
Before analysis, the hair samples were dipped in neutral detergent, then washed in
running water, distilled water and ion-free water in turn, then dried for 4 h at 60 ◦C
and cut into 0.5 cm long segments for acid digestion.
The As concentrations in hair, and blood samples were measured by hydride
generation coupled with ICP-AES following the method of Wang et al. (1999).
Hair (0.3 g) or blood (2 ml) samples were digested with concentrated nitric acid
(3 ml) and perchloric acid (1 ml) in tubes in electrothermal heating blocks until
the perchloride was almost driven off. After the samples were cooled, 2 ml hy-
drochloric acid were added and made to standard volume of 8 ml. The samples
were analysed by hydride generation inductively coupled plasma atomic emission
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spectrometry (HG- ICP-AES, ICP2020, Bird Instruments). The detection limit was
0.8–1.6 ng As ml−1 of acid digested samples. One standard hair sample (Chinese
hair, GBW0901, certified As concentration: 0.59± 0.07µg g−1, Chinese Standard
Sample Study Center, Chinese Academy of Measurement Sciences) was randomly
analysed twice with each batch of collected hair. The As concentration obtained
for the standard sample of hair was 0.58 ± 0.03µg g−1(n = 7).
Selenium in hair and blood samples was analysed by a 2,3-diaminonaphthalene
fluorescence method based on hair (0.5 g) or blood (2 ml) following digestion in
nitric/perchloric acid mixture as described in KSD Group (1977). Selenium was
measured in extracted samples by fluorimetry (Hatachi, MPF-11) at 377 nm (ex-
citation) and 522 nm (emission). The limit of detection was 0.002µg Se ml−1 and
relative standard deviation was 2.74%.
2.7. STATISTICAL METHODS
The difference of clinical change rate between the Se-group and the placebo-group
was statistically analysed using two proportions test method and As concentration
differences were analysed using two samples t-test. All the data were analysed
using MINITAB (release 13.1, MINITAB INC). Results for those farmers who
were sampled on each occasion throughout the trial have been calculated as a
group. The results have then been compared with the average values of all samples
collected.
3. Results
3.1. SELENIUM SUPPLEMENTATION RESULTS
Table II shows the changes in Se concentrations in blood and hair of farmers who
were sampled on each occasion. The Se concentration in the placebo-group for
both blood and hair remained constant throughout, while it increased in both hair
and blood throughout the trial. Exactly the same conclusions were revealed when
all analytical data were included.
3.2. ARSENIC CONCENTRATION CHANGES IN BLOOD AND HAIR
Figure 1(a) and Table III show changes in blood and hair As concentrations in both
the Se-group and the placebo-group who were sampled on each occasion through-
out the 14-month trial. Hair As concentration decreased consistently throughout the
trial in the Se-group compared with the placebo-group. Blood As concentrations
also decreased significantly in the Se-group compared with the placebo-group.
Essentially, the same results were recorded when all farmer data were included
(Figure 1(b)).
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TABLE II
Average Se concentrations in blood and hair throughout the trial, using only those farmers that were
sampled throughout the trial
0 month 3rd month 9th month 14th month No. of
cases
Blood (µg ml−1)
Se-group 0.130 ± 0.004 0.156 ± 0.004 0.163± 0.003 0.186 ± 0.003 54
Placebo-group 0.137 ± 0.005 0.139 ± 0.004 0.138± 0.003 0.133 ± 0.003 29
P-value >0.1 <0.01 <0.01 <0.01
Hair (µg g−1)
Se-group 0.431 ± 0.01 0.477 ± 0.01 0.503± 0.02 0.502 ± 0.01 54
Placebo-group 0.470 ± 0.01 0.465 ± 0.009 0.455± 0.02 0.478 ± 0.009 29
P-value <0.05 <0.05 <0.05 <0.05
Figure 1(a). Charts show blood (a) and hair (b) As concentration, using only the data of farmers
sampled on every occasion throughout the trial. Values are mean ± S.E.
Mean As concentrations in blood of >0.025µg ml−1 and >0.6µg g−1 in hair are
criteria of endemic arsenism (MOH, 1994). Using these criteria, it is significant
that both mean blood As concentrations and hair As concentrations of the Se-
group decreased to around these values by month 14 (i.e. 0.015µg ml−1 blood,
0.680µg g−1 hair) in those farmers who were sampled on each occasion. Similar
results apply to the all-farmer data.
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TABLE III
Average blood and hair arsenic concentration throughout the trial, using only those farmers that were
sampled throughout the trial
0 month 3rd month 9th month 14th month No. of
cases
Blood As (µg ml−1)
Se-group 0.051 ± 0.004 0.056 ± 0.006 0.023± 0.001 0.015 ± 0.001 54
Placebo-group 0.064 ± 0.008 0.041 ± 0.004 0.031± 0.003 0.024 ± 0.002 29
P-value >0.10 <0.05 <0.01 <0.001
Hair As (µg g−1)
Se-group 2.57± 0.16 2.15 ± 0.15 1.23± 0.10 0.680 ± 0.06 54
Placebo-group 2.62± 0.34 2.42 ± 0.31 2.01± 0.26 1.25± 0.16 29
P-value >0.1 <0.1 <0.05 <0.001
Figure 1(b). Charts show blood (a) and hair (b) As concentration using data from all farmers sampled.
Values are mean ± S.E.
3.3. SELENIUM SUPPLEMENTATION EFFECTS ON SKIN LESIONS
3.3.1. General improvement in skin lesions
All the adults in the trial had, at the commencement, developed one or more types
of skin lesions arising from arsenism. An analysis of only those farmers who had
provided blood and hair samples on each occasion showed that 7.4% of adults
were affected by only one kind of skin lesion (single lesion) in the Se-group, and
10.3% in the placebo-group (Table IVa). Some 25.9% of the adults in Se-group
and 24.1% of the adults in the placebo-group were affected by two kinds of skin
lesions (double lesions) and 66.7% of the adults in the Se-group and 65.5% adults
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TABLE IVa
Skin lesion improvements after 14 months of Se supplementation, using only those farmers whose
hair and blood were sampled on each occasion
Skin lesions Affected Affected Improved Improvement P-value
cases rate (%) cases (%) rate (%)
Single lesion
Se-group 4 7.4 1 18.5 <0.01
Placebo-group 3 10.3 0 0
Double lesions
Se-group 14 25.9 10 71.4 <0.01
Placebo-group 7 24.1 2 28.6
Triple lesions
Se-group 36 66.7 22 61.1 <0.01
Placebo-group 19 65.5 3 15.8
Total
Se-group 54 100.0 33 61.1 <0.01
Placebo-group 29 100 5 17.2
in placebo-group were affected by all three skin lesions (triple lesions). After 14
months Se supplementation, a total of 33 of the 54 adults (61.1%) had improved
in any one, two or three kinds of skin lesions. Among them, 18.5% of single skin
lesion affected adults, 71.4% of double skin lesions affected adults and 61.1% of
triple skin lesions affected adults had improved.
In the placebo-group, only five of the 29 (17.2%) affected adults had improve-
ments in their skin lesions. The improvement of single, double and triple skin
lesions were much lower than those in Se-group (Table IVa). The results indicate
that Se supplementation is more effective in the improvement of severe skin lesions
affected patients compared with those in the placebo-group.
An analysis of all the farmers in the trial (i.e. 100 and 86 in the Se-group and
placebo-group, respectively) showed comparable findings (Table IVb), namely that
67.0% of the lesions in the Se-group and 24.4% in the placebo-group had improved.
3.3.2. Improvement in each kind of skin lesion
Hyperkeratosis is the most prevalent skin lesion in the study area, with an oc-
currence rate of 94.4% in the Se-group and 96.6% in the placebo-group at the
commencement of the trial when considering only those farmers whose blood and
hair was sampled on each occasion (Table Va). The second most prevalent skin
lesion was depigmentation, with an occurrence rate of 92.6% in the Se-group and
86.2% in the placebo-group, and the least prevalent was that of pigmentation with
the rate of 70.4% in the Se- group and 51.7% in the placebo-group.
368 LINSHENG YANG ET AL.
TABLE IVb
General skin lesion improvements after 14 months of Se supplementation
Skin lesions Affected Affected Improved Improvement P-value
cases rate (%) cases (%) rate (%)
Single lesion
Se-group 7 7.0 2 28.6 1.00
Placebo-group 7 8.1 2 28.6
Double lesions
Se-group 36 36.0 28 77.8 <0.002
Placebo-group 29 33.7 12 41.4
Triple lesions
Se-group 57 57.0 37 64.9 <0.01
Placebo-group 50 58.1 7 14.0
Total
Se-group 100 100.0 67 67.0 <0.01
Placebo-group 86 100 21 24.4
After 14 months of Se supplementation, 41.2% of the hyperkeratosis affected,
50.0% of depigmentation affected and 44.7% of pigmentation affected adults had
improved, but only 7.1, 12.0, and 6.7% in the placebo-group, respectively, had
improved.
TABLE Va
Details of skin lesion improvement following 14 months of
selenium supplementation, using only those farmers whose
hair and blood were sampled on each occasion
Total affected Total improvement
Cases Rate (%) Cases Rate (%)
Se-group 54 33
Hyperkeratosis 51 94.4 21 41.2
Depigmentation 50 92.6 25 50.0
Pigmentation 38 70.4 17 44.7
Placebo-group 29 5
Hyperkeratosis 28 96.6 2 7.1
Depigmentation 25 86.2 3 12.0
Pigmentation 15 51.7 1 6.7
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TABLE Vb
Details for all farmers of skin lesion improvement following 14
months of selenium supplementation
Lesion type Total affected Total improvement
Cases Rate (%) Cases Rate (%)
Se-group
Hyperkeratosis 96 96.0 35 36.5
Depigmentation 91 91.0 45 49.3
Pigmentation 62 62.0 26 41.9
Placebo-group
Hyperkeratosis 82 95.4 12 14.6
Depigmentation 79 91.9 15 19.0
Pigmentation 51 59.3 5 9.8
An analysis of all the farmers in the trial showed comparable results (Table Vb).
Namely, that after 14 months, Se supplementation had improved skin lesions com-
pared with the placebo-group.
4. Discussion and conclusion
In this study we report a statistically significant decrease in arsenism skin lesions
and As in blood and hair when compared with the placebo-group, following daily
oral Se supplementation and a supply of ‘As-free’ drinking water. These conclu-
sions applied both to the group of farmers who were sampled on each occasion,
and to the whole group of farmers, although the S.E. of the means for blood and
hair analyses were larger in the former group due to the smaller number of farm-
ers. Results for the decrease in As concentration in hair clearly illustrates these
results as hair represents an integrated exposure, while blood As concentrations
only reflects short-term exposure (WHO, 1981). We do not know the significance
of the elevated As concentration in blood at the 3 months sampling period in the
Se supplementation group.
Selenium has been known as an antagonist of As toxicity for many years
(Levander and Baumann, 1966) and has been reported to stimulate the excretion
of As in the bile of rats (WHO, 1981). Recent studies show that Se can form the
Gailer compound, seleno-bis(S-glutathionyl)arsinium ion that is excreted in the
bile of rabbits and thus is a part of a detoxification process (Aposhian et al., 1999).
Selenium can also increase the methylation of arsenic many fold (Aposhian et al.,
1999).
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Se supplementation has been involved in the treatment of various human condi-
tions. In China, Se-enriched yeast has been used as a supplement to control Keshan
and Keshin-Beck Diseases (Alfthan et al., 2000), to protect against hepatitis B virus
and primary liver cancer (Yu et al., 1997), to improve liver function of alcoholic cir-
rhosis (Vangossum and Neve, 1995), to antagonise mercury poisoning (Seppanen
et al., 2000), and to increase the immuno-stimulatory properties of elderly people
(Peretz et al., 1991). The daily Se supplements are between 100 and 200µg, the
same as used in the present trial.
With the increasing discovery of chronic arsenism in many parts of the world
including Bangladesh, India, Thailand, China, China-Taiwan, Japan (Mandal et al.,
1996; Choprapawon and Ajjimangkul, 1999) the need for treatment of arsenism
is obvious. Indicators that can be used as effective tools for the reporting and
management of arsenism within different policy contexts is a further important
requirement (Peterson et al., 2001).
We report in this paper that there was a marked improvement in skin lesions
following 14 months of Se supplementation in both farmers who were sampled on
each occasion as well as in the whole group of farmers. However, there are few
reports in the literature that the use of a chelating agent or nutrient supplement
can improve arsenism skin lesions. Although Clark et al. (1996) found that Se
supplementation did not protect against the development of skin cancers, many
areas of the world in which chronic As exposure occurs are low in Se (Aposhian
et al., 1999). Clearly, much more research is required on the role of Se as a nutrient
to prevent, or reduce the impact of arsenism.
In an earlier study we examined data from five arsenism locations in Inner
Mongolia and reported a positive linear exposure–response relationship between
As concentration in drinking water and the prevalence rate of skin lesions (Yang
et al., 2002b). Further results have shown that the concentration of As in hair cor-
relates with these clinical stages (Yang et al., 2002a). However, data from Xinjiang,
another arsenism area in China, showed essentially the same slope of the exposure–
response regression model but it was displaced to higher As concentrations in
the drinking water. The reasons for the differences between Inner Mongolia and
Xinjiang are not clear, perhaps they relate to differences of nutritional status, in-
cluding Se? Indeed Biswas et al. (1999) have reported that poor people were af-
fected to a greater extent in As-affected villages in West Bengal. Whether their
Se concentration was low, or whether a possible protein deficiency led to a de-
pletion of binding sites for As and its metabolites is unknown. Vahter (1999) has
also mentioned that subjects with a poor nutritional status may have an increased
susceptibility to As toxicity. However, detailed studies on the nutritional intakes
and As toxicity are essentially lacking.
This trial although limited by its relatively small size, has provided some evid-
ence of the usefulness of Se supplementation for people affected by arsenism. But
the study was a placebo-controlled intervention trial, not a randomised, controlled,
double blind trial involving all socio-economic groups and different ethnic people.
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A large trial including a high arsenic drinking water exposure control, compared
with both Se supplementation groups and placebo-groups, should be undertaken
in several provinces of China where arsenism is a serious endemic disease. But as
the local farmers in endemic arsenism areas in China understand the pathogeny, it
will be difficult for ethical conditions to conduct any long-term trial involving a
continued high arsenic in drinking water control group.
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